A Phase I, Open-Label Study to Evaluate the Effect of Rifampin on the Single Dose Pharmacokinetics, Safety and Tolerability of BMS-986224 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 06 Sep 2018
Price : $35 *
At a glance
- Drugs BMS-986224 (Primary) ; Rifampicin
- Indications Chronic heart failure
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 28 Aug 2018 Status changed from recruiting to completed.
- 03 Jul 2018 Status changed from not yet recruiting to recruiting.
- 26 Jun 2018 New trial record